Lower urinary tract symptoms secondary to benign prostatic hyperplasia in 2017: update from the 32nd annual congress of European association of urology


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review article summarizes new data on mono- and combination therapy for male urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). A special attention is paid to the reports made at the 32nd Annual EAU Congress and published in the congress proceedings. The article outlines new data on the epidemiology of LUTS secondary to BPH, recent changes in the pathogenesis of LUTS, provides a critical analysis of the latest publications on а-blockers, 5а-reductase inhibitors, antimuscarinics and phosphodiesterase type 5 inhibitors in pharmacological management of LUTS. The authors analyze recent data on the effectiveness of surgical methods for treating BPH

Full Text

Restricted Access

About the authors

D. V Ergakov

D.D. Pletnev CCH

Email: dergakov@mail.ru
Urologist at the Department of Urology №2, D.D. Pletnev CCH; Associate Professor at Department of Urology and Andrology Moscow, Russia

A. G Martov

D.D. Pletnev CCH; A.I. Burnazyan Federal Medical Biophysical Center, FMBA of Russia

Email: martovalex@mail.ru
Dr.Med.Sci., Prof., the Honored Physician of Russia, Head of the Department of Urology and Andrology, A.I. Burnazyan Federal Medical Biophysical Center, FMBA of Russia, Prof. at the Department of Endoscopic Urology, PMACPE, Head of the Department of Urology, D.D. Pletnev CCH, Moscow HD Moscow, Russia

References

  1. Nascimento-Viana J.B., Carvalho A.E., Nasciutti L.E. et al. New Multi-target Antagonists of a1A-, a1D-Adrenoceptors and 5-HT1A Receptors Reduce Human Hyperplastic Prostate Cell Growth and the Increase of Intraurethral Pressure. J Pharmacol Exp Ther 2016;356:212-222.
  2. Park Y.H., Kim T.H., Lee S.W. et al. Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms. Low Urin Tract Symptoms. 2017;9(2):75-78.
  3. Kim S.E., Ko I.K., Hwang L. et al. An animal study to compare the degree of the suppressive effects on the afferent pathways of micturition between tamsulosin and sildenafil. J Biomed Sci. 2013; 20(1): 81.
  4. Hennenberg M., Tamalunas A., Wang Y. et al. Inhibition of agonist-induced smooth muscle contraction by picotamide in the male human lower urinary tract outflow region. Eur J Pharmacol. 2017;803:39-47.
  5. De Nunzio C., Giglio S., Stoppacciaro A. et al. Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia. Oncotarget. 2017. doi: 10.18632/oncotarget.15144. [Epub ahead of print].
  6. Gacci M., Sebastianelli A., Salvi M. et al. Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study. BMC Urol. 2017;17(1):22.
  7. Gacci M., Vignozzi L., Sebastianelli A. et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis. 2013;16(1):101-106.
  8. Nickel J.C., Roehrborn C.G., Castro-Santamaria R. Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention. J Urol. 2016;196(5):1493-1498.
  9. Vignozzi L., Gacci M., Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol. 2016;13(2):108-119.
  10. Venderbos L.D., Aluwini S., Roobol M.J. et al. Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer. Qual Life Res. 2017 Feb 6. doi: 10.1007/s11136-017-1507-7.
  11. Roehrborn C.G., Oyarzabal Perez I., Roos E.P. et al. Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study. World J Urol. 2017;35(3):421-427.
  12. Biers S, Sievert KD, Thiruchelvam N. Overactive bladder syndrome and lower urinary tract symptoms after prostate cancer treatment. Curr Opin Urol. 2017;27(3):307-313.
  13. Oelke M., Martinelli E. Pharmacological treatment of benign prostatic hyperplasia. Urologe A. 2016, 55(1):81-94.
  14. Oelke M., Bachmann A., Descazeaud A. et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1): 118-140.
  15. Kim S.J., Shin I.S., Eun S.J. et al. Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients. Int Neurourol J. 2017 Mar 24;21(1):29-37.
  16. Unger J.M., Till C., Thompson I.M. Jr. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2016;108(12).
  17. Gacci M., Andersson K.E., Chapple C. et al. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol. 2016;70(1):124-133.
  18. Haider A., Yassin A., Haider K.S. et al. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. Vasc Health Risk Manag. 2016;12:251-261.
  19. Lee S.H., Park T.J., Bae M.H. et al. Impact of treatment with statins on prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia. Korean J Urol. 2013;54(11):750-755.
  20. Rosier P.F., de Wildt M.J., Wijkstra H. et al. Clinical diagnosis of bladder outlet obstruction in patients with benign prostatic enlargement and lower urinary tract symptoms: development and urodynamic validation of a clinical prostate score for the objective diagnosis of bladder outlet obstruction. J Urol. 1996;155(5):1649- 1654.
  21. Meyer C.P., Allard C.B., Sammon J.D. et al. Data on Medicare eligibility and cancer screening utilization. Data Brief. 2016 Feb 27;7:679-681.
  22. Leow J.J., Chang S.L., Meyer C.P. et al. Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database. Eur Urol. 2016;70(5):837-845.
  23. Cindolo L., Ruggera L., Destefanis P. et al. Vaporize, anatomically vaporize or enucleate the prostate? The flexible use of the GreenLight laser. Int Urol Nephrol. 2017;49(3):405-411.
  24. Peyronnet B, Misrai V, Aho T. et al. Greenlight® users should move from photoselective vaporization to endoscopic enucleation in larger prostates. World J Urol. 2017 Apr 28. doi: 10.1007/s00345-017-2042-4. [Epub ahead of print].
  25. Xin Z., Huang Y., Lu J. et al. Addition of antimuscarinics to alphablockers for treatment of lower urinary tract symptoms in men: a meta-analysis. Urology. 2013;82(2):270-277.
  26. Cornu J.-N. Current advances in male lower urinary tract symptoms assessment and management: more and more questions. Curr Opin Urol. 2016;26(1):1-2.
  27. Cornu J.-N. Bipolar, Monopolar, Photovaporization of the Prostate, or Holmium Laser Enucleation of the Prostate: How to Choose What’s Best? Urol Clin North Am. 2016;43(3):377-384.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies